Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An exploratory, open label, multicenter parallel group study to evaluate the effects of single and repeat dosing of SB-751689 [ronacaleret] (400 mg or 100 mg) or rhPTH (1-34) [teriparatide] on the fractional renal excretion of calcium and phosphate in healthy postmenopausal females.

Next Previous
Trial Profile

An exploratory, open label, multicenter parallel group study to evaluate the effects of single and repeat dosing of SB-751689 [ronacaleret] (400 mg or 100 mg) or rhPTH (1-34) [teriparatide] on the fractional renal excretion of calcium and phosphate in healthy postmenopausal females.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ronacaleret (Primary) ; Teriparatide (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 11 Sep 2009 Results presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research.
  • 18 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 02 Oct 2007 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top